In MS Patients, Ozanimod Surpasses Avonex at Reducing Relapses, Phase 3 Trial Finds - Multiple Sclerosis News Today

In MS Patients, Ozanimod Surpasses Avonex at Reducing Relapses, Phase 3 Trial Finds  Multiple Sclerosis News Today

Oral ozanimod is more effective at reducing the frequency of relapses than Avonex (interferon beta-1a) in patients with relapsing forms of Multiple Sclerosis (MS), ...

Compound Created to Help Reconstruct Myelin in Mul...
Ofatumumab Bests Teriflunomide in Head-to-Head MS ...
 

Comments

No comments made yet. Be the first to submit a comment
Already Registered? Login Here
Guest
Sunday, 17 November 2019

 
 

Follow Us on Twitter

Follow Us On Twitter - Image